For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Vyndamax and Tafamidis meglumine represents a significant breakthrough . These innovative therapies protect the transthyretin protein, slowing its destructive build-up and alleviating the severity of the disease . Individuals are n… Read More